Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream - 24/08/11
Doi : 10.1016/j.jaad.2004.04.022
Oliverio Welsh, MD, Dr Sc a, ⁎ 
, Zulema Olazarán, MD a, Minerva Gómez, MD a, Julio Salas, MD a, Brian Berman, MD, PhD b
, Zulema Olazarán, MD a, Minerva Gómez, MD a, Julio Salas, MD a, Brian Berman, MD, PhD b a From the Departments of Dermatology at the University Hospital UANL Madero y Gonzalitos, Col. Mitras Centro Monterrey
b the University of Miami.
Reprint requests: Oliverio Welsh, MD, Dr Sc, Emeritus Professor (active), Coordinator of Basic Research, Department of Dermatology, University Hospital UANL, Madero y Gonzalitos, Col. Mitras Centro, Monterrey, NL, México.Monterrey, Mexico, and Miami, Florida
Abstract |
Ten patients with superficial infantile hemangiomas were treated with imiquimod 5% cream for up to 16 weeks. Four patients achieved complete clinical resolution, 3 had excellent improvement, one showed moderate improvement, and one patient did not respond to therapy. Imiquimod may be an effective alternative for the treatment of superficial hemangiomas.
Le texte complet de cet article est disponible en PDF.Plan
| This study was approved by the research and ethical committee of the post-graduate medical school UANL. Imiquimod 5% cream was donated for the patients by 3M Pharmaceuticals in Monterrey, Mexico. Dr Berman is a consultant for, a member of the speakers bureau of, and has received education grants from 3M Pharmaceuticals. |
© 2004
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 51 - N° 4
P. 639-642 - octobre 2004 Retour au numéro
Article précédent
- Topical imiquimod treatment of lentigo maligna: Clinical and histologic evaluation
- I. Kupfer-Bessaguet, G. Guillet, L. Misery, J.L. Carre, J.P. Leroy, Bruno Sassolas
- Motivating factors for attendance of skin cancer screenings
- Tyler R. Call, Kenneth M. Boucher, Brad L. Whiting, Marybeth Hart, Karen Newman, Anita Y. Kinney, Glen M. Bowen, John J. Zone, Donna Branson, Sancy A. Leachman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?